What does it do?
OptiBiotix Health PLC (LON:OPTI) has developed technologies that modulate the human microbiome – the collective genome of the microbes in the body. It has done so by creating microbial strains, compounds and formulations for use in food ingredients, supplements and active compounds that can impact on human physiology, deriving potential health benefits.
With an established pipeline of microbiome modulators, the firm is working on the prevention and management of chronic lifestyle diseases such as obesity, hypercholesterolemia and lipid profiles and diabetes.
Its product roster includes weight management lines SlimBiome and SlimBiome Medical, LPLDL (cholesterol) and SweetBiotix (sweetener).
How’s it doing?
In a comprehensive update on trading released on January 17, Optibiotix said total sales for the 12 months ended November 30 were £808,000. Adding in £617,000 from the disposal of a small tranche of shares it owns in sister company SkinBioTherapeutics, total income was £1.43mln, up from £541,614 a year earlier.
In terms of funding, the firm had just over £1.2mln in cash and trade debtors at the year-end, or £1.4mln once R&D tax credits are recovered. It also has a £7mln stake in SkinBioTherapeutics, which would support what it termed “capital growth”.
Recognised as key player
OptiBiotix has also been highlighted as a "key player" in a report on the status of the human microbiome market and its global outlook for 2020-2024.
The report from Market Study Report LLC (MSR) said over recent years the human microbiome market, which was valued at US$351.8mln in 2018, has witnessed “considerable growth on the back of rising incidences of diabetes, growing geriatric population, and continuous research and development conducted by pharmaceutical manufacturers and academia”.
“In addition, growing sedentary lifestyle, increasing incidence of diabetes and chronic diseases globally have contributed to the growth rate of Human Microbiome market”, the report said, adding that these factors were “anticipated to provide higher momentum to the market growth” in the coming years.
The report also predicted that “increasing collaboration in the industry between market players and academia to generate data and treatment for the diseases including gut related problems which can be tackled with the help of microbiota” will facilitate the growth of the market.
- On 6 April, OptiBiotix signed a contract manufacturing agreement with French food supplements and nutrition group, Laboratoire PYC, for the exclusive rights to manufacture meal replacement shakes for the UK firm’s GoFigure weight management range
- In early April, the firm signed a contract manufacturing deal with a Danish company called Fipros for its to manufacture the weight management product SlimBiome under licence
- In late March, the company signed an exclusive licence agreement for its OptiBiome weight loss ingredient with Australian firm OptiPharm Pty Ltd